CHRS · TickerCove

CHRSCoherus Oncology, Inc.as of 2026-09-16

Horizon

Issued 2026-09-16 at $1.22 · now $1.22 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, CHRS has typically landed between $0.86 and $1.72 — a range of −29.8% to +40.8% from the issuance price $1.22.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

2,948 overlapping 1 month windows · 2014-11-06 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($1.22) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$1.22 · 9% of range

$1.1 low$2.51 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,408 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.9%

90% CI 51.7%–56.1%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−4.9%

typical move · IQR 26.5%

−29.8%worst (p90)+40.8%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 1 sells · 1 member

cluster tilt persisted, ~halved after 2021

Where CHRS has typically landed a month from the 2026-09-16 close of $1.22 — the range is history, not a prediction.

now $1.22 (+0.0%)
typical $1.16 (-4.9%)
middle 50% $0.9982–$1.32
90% range $0.8565–$1.72

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,948 windows spanning 2014-11-06 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2023-10-11	−58.1%	−58.1%	+0.8%
2023-10-12	−56.9%	−56.9%	+4.3%
2023-10-13	−54.9%	−58.3%	+1.0%
3 best
2024-11-04	+155.2%	+0.0%	+155.2%
2024-11-01	+136.5%	−7.3%	+136.5%
2024-11-06	+134.9%	+0.0%	+136.3%

2,948 overlapping windows · 2014-11-06 – 2026-09-16 · not cherry-picked

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~12 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

58%

+4.4%

n=12

Feb

42%

−1.4%

n=12

Mar

50%

+0.5%

n=12

Apr

58%

−2.4%

n=12

May

42%

−3.4%

n=12

Jun

33%

−2.6%

n=12

Jul

58%

+9.8%

n=12

Aug

75%

+10.4%

n=12

Sep

17%

−9.3%

n=12

Oct

36%

−6.3%

n=11

Nov

45%

−0.5%

n=11

Dec

58%

+4.1%

n=12

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2025-05-23	Wahlstrom Mats	director	Sale	99,988 @ $0.74	$74K	−100.0% of holding	−9.8%	+39.0%	0	Form 4 · filed 5 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

100 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-06-05	Newcomer Lee Nisley	director	Award / grant	30,000	30,000	Form 4
2026-06-05	Newcomer Lee Nisley	director	Award / grant	60,000	60,000	Form 4
2026-06-05	Newton Charles W.	director	Award / grant	30,000	30,000	Form 4
2026-06-05	Karachun Rita A	director	Award / grant	30,000	30,000	Form 4
2026-06-05	Karachun Rita A	director	Award / grant	60,000	60,000	Form 4
2026-06-05	Satvat Ali J.	director	Award / grant	30,000	30,000	Form 4
2026-06-05	Satvat Ali J.	director	Award / grant	60,000	60,000	Form 4
2026-06-05	Newton Charles W.	director	Award / grant	60,000	60,000	Form 4
2026-06-05	Wahlstrom Mats	director	Award / grant	30,000	30,000	Form 4
2026-06-05	Wahlstrom Mats	director	Award / grant	60,000	60,000	Form 4
2026-06-05	O'Donnell-Tormey Jill	director	Award / grant	30,000	30,000	Form 4
2026-06-05	O'Donnell-Tormey Jill	director	Award / grant	60,000	60,000	Form 4
2026-06-05	Ryan Michael Lee	director	Award / grant	30,000	30,000	Form 4
2026-06-05	Ryan Michael Lee	director	Award / grant	60,000	60,000	Form 4
2026-05-29	Lanfear Dennis M	director	Award / grant	500,000	500,000	Form 4
2026-05-29	Lanfear Dennis M	director	Award / grant	125,000	125,000	Form 4
2026-05-29	Lanfear Dennis M	director	Award / grant	402,500	402,500	Form 4
2026-05-29	Lanfear Dennis M	director	Award / grant	402,500	402,500	Form 4
2026-05-29	Lanfear Dennis M	director	Award / grant	225,000	225,000	Form 4
2026-05-29	McMichael Bryan J	officer	Disposition	100,000	0	Form 4
2026-05-29	McMichael Bryan J	officer	Disposition	25,000	0	Form 4
2026-05-29	McMichael Bryan J	officer	Disposition	15,000	0	Form 4
2026-05-29	McMichael Bryan J	officer	Disposition	25,000	0	Form 4
2026-05-29	McMichael Bryan J	officer	Disposition	25,000	0	Form 4
2026-05-29	McMichael Bryan J	officer	Disposition	30,000	0	Form 4
2026-05-29	McMichael Bryan J	officer	Award / grant	100,000	100,000	Form 4
2026-05-29	McMichael Bryan J	officer	Award / grant	25,000	25,000	Form 4
2026-05-29	McMichael Bryan J	officer	Award / grant	15,000	15,000	Form 4
2026-05-29	McMichael Bryan J	officer	Award / grant	25,000	25,000	Form 4
2026-05-29	McMichael Bryan J	officer	Award / grant	25,000	25,000	Form 4
2026-05-29	McMichael Bryan J	officer	Award / grant	30,000	30,000	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	200,000	0	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	400,000	0	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	450,000	0	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	500,000	0	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	500,000	0	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	125,000	0	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	402,500	0	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	402,500	0	Form 4
2026-05-29	Lanfear Dennis M	director	Disposition	225,000	0	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures iiDisclosures shown as facts. A purchase “cluster” (≥2 members of Congress filing a buy within 90 days) has historically preceded modestly higher forward returns — and it persisted out-of-sample, though it roughly halved after 2021 (see below). A descriptive historical tendency, not a signal to trade and not used in our forecast. See /methodology.

As of 2026-09-16 · point-in-time by filed date

Purchase clusters · 2015–2021 (dev)+45 bp/mo vs baseline · up-rate 59.3% vs 57.3% · n=31,607 cluster ticker-weeks

Purchase clusters · 2022–2026 (out-of-sample)+32 bp/mo vs baseline · up-rate 54.0% vs 53.3% · n=27,793

A cluster = ≥2 members of Congress filing a purchase within 90 days. The historical tilt persisted after 2021 but roughly halved (+45 → +32 bp/mo forward 1-month vs the S&P 500 weekly-grid baseline). Descriptive historical tendency — not a signal to trade, and not used in our forecast (audition-log 2026-07-27, recomputed 2026-09-08).

Member	Chamber	Type	Filed	Traded	Size
Shri Thanedar	House	sale	2023-02-09	2023-01-23	$15–50K

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Seasonality · by month i